Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


Community Oncology Alliance Commends Trump Administration for Plan to Lower Drug Costs for Patients


Washington, DC, Jan. 31, 2019 — The Community Oncology Alliance (COA) applauds President Donald Trump, Health and Human Services Secretary Alex Azar, Inspector General Daniel Levinson, and HHS staff for the just released, ambitious proposal to overhaul the nation’s secretive drug rebate system. This move will lower drug prices for all Americans by finally ensuring that patients receive the benefit of negotiated drug discounts, not plan sponsors and pharmacy benefit managers (PBM). For decades, corporate PBM middlemen have pocketed billions of dollars in record profits from the shadowy network of rebates they negotiate with manufacturers, while patients with cancer and other serious diseases have continued to bear the burden of high drug costs. This rebate system has served to drive drug list prices higher and higher, benefited PBM middlemen, and fueled out-of-pocket drug costs for patients. As HHS noted in the plan’s announcement, “nearly every drug company taking a January 2019 price increase announced that all or nearly all of the increase was being paid to PBMs or insurers as rebates.” The Administration’s proposal will directly lower drug prices and out-of-pocket costs by ensuring that patients, not PBM middlemen, receive the benefit of the discounts from manufacturers. This plan is extremely good news for patients who will now directly benefit from discounts and lower drug prices. Today’s announcement is a concrete step the Administration has taken to reduce the incredibly negative influence of PBM middlemen. As it stands today, physicians report that PBM middlemen in Part D reduce care choices, drive up costs, increase administrative burdens, and interfere with physician-patient decision making. Over the last three years, COA has documented real-life horror stories from practices and physicians about patients battling cancer who have suffered at the hands of PBMs due to delayed coverage decisions, denial of needed treatments, impenetrable bureaucracies, and failure to receive medications in a timely manner. COA encourages the Administration to next fix murky direct and indirect remuneration fees – so called DIR fees – that PBMs extort from pharmacy providers and that further drive up list prices of drugs. DIR Fees, which have no basis in regulation or law, artificially inflate the costs paid by Medicare beneficiaries for prescription drugs, pushing them into the Medicare Part D “donut hole” faster, fueling rising drug prices, and ultimately adding to the burden on taxpayers. COA is actively working to address the high cost of cancer drugs and services. As the frontline providers of care for the majority of Americans battling cancer, independent community oncologists are uniquely positioned to give insight into the impact of federal policymaking on patients, providers, and the overall health care system. ### About the Community Oncology Alliance: The majority of Americans battling cancer receive treatment in the community oncology setting. Keeping patients close to their homes, families, and support networks lessens the impact of this devastating disease. Community oncology practices do this while delivering high-quality, cutting-edge cancer care at a fraction of the cost of the hospital setting. The Community Oncology Alliance (COA) advocates for community oncology and smart public policy that ensures the community cancer care system remains healthy and able to provide all Americans with access to local, quality, affordable cancer care. Learn more at

Community Oncology Alliance  (202) 729-8147  

Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.